{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:06:34Z","timestamp":1784073994955,"version":"3.55.0"},"reference-count":128,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>New and emerging non-glucocorticoid therapies for classic congenital adrenal hyperplasia (CAH) can reduce adrenocorticotropic hormone-mediated androgen production, allowing for glucocorticoid (GC) dose reductions. With the approval of crinecerfont as an adjunctive treatment to GC replacement for patients with classic CAH 4 years of age and older, expert recommendations were developed to provide guidance for GC reduction in pediatric patients after starting crinecerfont.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Acquisition<\/jats:title>\n                    <jats:p>In December 2024, 11 expert endocrinologists participated in a panel to provide input on strategies and considerations when reducing GC doses after introducing crinecerfont. A smaller panel reconvened in January 2025 to review previous discussions and develop recommendations for GC dose reduction after starting crinecerfont in pediatric patients with classic CAH (4-17 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Synthesis<\/jats:title>\n                    <jats:p>Approaches to GC reduction should be tailored to individual clinical goals, cortisol needs, and lifestyle. In pediatric patients, GC dose reductions should be guided by androgen concentrations, with the general goal of maintaining androgens near normal range to achieve normal growth and normalize bone age maturation while also minimizing complications from long-term GC exposure. Glucocorticoid doses should be reduced gradually with frequent monitoring and should not be decreased below the dose needed for physiologic cortisol replacement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The approval of crinecerfont has initiated a shift in the treatment approach for classic CAH, in which GCs are used at lower doses predominantly for cortisol replacement. These recommendations will become increasingly relevant as treatment for these patients continues to shift toward a new paradigm of physiologic GC replacement with adjunctive control of androgens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag192","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:09:03Z","timestamp":1777637343000},"page":"e1937-e1950","source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-3947","authenticated-orcid":false,"given":"Natalie J","family":"Nokoff","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz , Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Y","family":"Fechner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Hospital , Seattle, WA 98105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-3569","authenticated-orcid":false,"given":"Mimi S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles , Los Angeles, CA 90027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rutgers-Robert Wood Johnson Medical School , New Brunswick, NJ 08901 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah P","family":"Merke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Institutes of Health Clinical Center , Bethesda, MD 20892, USA"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development , Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-3629","authenticated-orcid":false,"given":"Kyriakie","family":"Sarafoglou","sequence":"additional","affiliation":[{"name":"Divisions of Pediatric Endocrinology and Genetics and Metabolism, University of Minnesota Medical School , Minneapolis, MN 55454, USA"},{"name":"Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy , Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L","family":"Hartzell","sequence":"additional","affiliation":[{"name":"Medical Affairs, Neurocrine Biosciences, Inc. , San Diego, CA 92130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Affairs, Neurocrine Biosciences, Inc. , San Diego, CA 92130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thornton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Cook Children's Medical Center , Fort Worth, TX 76104, USA"},{"name":"Department of Pediatrics, Burnett School of Medicine, Texas Christian University , Fort Worth, TX 76104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"11","key":"2026071419574998800_dgag192-B1","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2026071419574998800_dgag192-B2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"issue":"10372","key":"2026071419574998800_dgag192-B3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(22)01330-7","article-title":"Congenital adrenal hyperplasia","volume":"401","author":"Auer","year":"2023","journal-title":"Lancet"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgae535","article-title":"Genetics and pathophysiology of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Yang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10108","key":"2026071419574998800_dgag192-B5","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"2026071419574998800_dgag192-B6","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM200011093431903","article-title":"Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency","volume":"343","author":"Merke","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071419574998800_dgag192-B7","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1210\/clinem\/dgab600","article-title":"Low adrenomedullary function predicts acute illness in infants with classical congenital adrenal hyperplasia","volume":"107","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419574998800_dgag192-B8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419574998800_dgag192-B9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/jim-2019-000999","article-title":"Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings","volume":"68","author":"Miller","year":"2020","journal-title":"J Investig Med"},{"issue":"9","key":"2026071419574998800_dgag192-B10","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/clinem\/dgad134","article-title":"Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management","volume":"108","author":"Sarafoglou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419574998800_dgag192-B11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17446651.2025.2450423","article-title":"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms","volume":"20","author":"Bancos","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026071419574998800_dgag192-B12","volume-title":"CRENESSITY\u2122 (Crinecerfont) Capsules and CRENESSITYTM (Crinecerfont) Oral Solution Full Prescribing Information","author":"Neurocrine Biosciences, Inc","year":"2024"},{"issue":"12","key":"2026071419574998800_dgag192-B13","doi-asserted-by":"crossref","first-page":"E2715","DOI":"10.1210\/jc.2014-2957","article-title":"Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"99","author":"Falhammar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574998800_dgag192-B14","doi-asserted-by":"crossref","first-page":"E1597","DOI":"10.1210\/jc.2014-1274","article-title":"Decreased adrenomedullary function in infants with classical congenital adrenal hyperplasia","volume":"99","author":"Kim","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419574998800_dgag192-B15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","article-title":"Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children","volume":"167","author":"Thornton","year":"2015","journal-title":"J Pediatr"},{"issue":"1","key":"2026071419574998800_dgag192-B16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia\u2013current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"issue":"9477","key":"2026071419574998800_dgag192-B17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"issue":"6458","key":"2026071419574998800_dgag192-B18","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/bmj.289.6458.1603","article-title":"Hypoglycaemia during illness in children with congenital adrenal hyperplasia","volume":"289","author":"Hinde","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"2026071419574998800_dgag192-B19","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1210\/jc.2018-00208","article-title":"Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia","volume":"103","author":"El-Maouche","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B20","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgae563","article-title":"Clinical manifestations and treatment challenges in infants and children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Nokoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419574998800_dgag192-B21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000489385","article-title":"Clitoromegaly in childhood and adolescence: behind one clinical sign, a clinicals sea","volume":"12","author":"Iezzi","year":"2018","journal-title":"Sex Dev"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B22","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1210\/clinem\/dgae696","article-title":"Clinical manifestations and challenges in adolescent and adult females with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Engberg","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574998800_dgag192-B23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000494903","article-title":"Androgens in congenital adrenal hyperplasia","volume":"53","author":"Pignatelli","year":"2019","journal-title":"Front Horm Res"},{"issue":"2","key":"2026071419574998800_dgag192-B24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/beem.2002.0198","article-title":"Long-term consequences of childhood-onset congenital adrenal hyperplasia","volume":"16","author":"White","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2026071419574998800_dgag192-B25","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026071419574998800_dgag192-B26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1515\/jpem-2016-0156","article-title":"Growth curves for congenital adrenal hyperplasia from a national retrospective cohort","volume":"29","author":"Bretones","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2026071419574998800_dgag192-B27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"issue":"4","key":"2026071419574998800_dgag192-B28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/clinem\/dgaf554","article-title":"The importance of disease-specific growth charts for children with congenital adrenal hyperplasia","volume":"111","author":"Sarafoglou","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419574998800_dgag192-B29","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1210\/en.2019-00101","article-title":"Physiological and pathological androgen actions in the ovary","volume":"160","author":"Astapova","year":"2019","journal-title":"Endocrinology"},{"issue":"2","key":"2026071419574998800_dgag192-B30","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1210\/clinem\/dgaa801","article-title":"Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: a population-based cohort study","volume":"106","author":"Hirschberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419574998800_dgag192-B31","doi-asserted-by":"crossref","first-page":"624823","DOI":"10.1186\/1687-9856-2009-624823","article-title":"Testicular adrenal rest tumours in congenital adrenal hyperplasia","volume":"2009","author":"Claahsen-van der Grinten","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"issue":"3","key":"2026071419574998800_dgag192-B32","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/clinem\/dgaf498","article-title":"Longitudinal characterization and sonographic staging of testicular adrenal rest tumors","volume":"111","author":"Vaid","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B33","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1210\/clinem\/dgae718","article-title":"Challenges in adolescent and adult males with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Claahsen-van der Grinten","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419574998800_dgag192-B34","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-20-1093","article-title":"Management of endocrine disease: gonadal dysfunction in congenital adrenal hyperplasia","volume":"184","author":"Claahsen-van der Grinten","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026071419574998800_dgag192-B35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/cen.13001","article-title":"Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency","volume":"84","author":"King","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026071419574998800_dgag192-B36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.fertnstert.2007.03.051","article-title":"Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage","volume":"89","author":"Claahsen-van der Grinten","year":"2008","journal-title":"Fertil Steril"},{"issue":"4","key":"2026071419574998800_dgag192-B37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000444169","article-title":"Carotid intima-media thickness is associated with increased androgens in adolescents and young adults with classical congenital adrenal hyperplasia","volume":"85","author":"Kim","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"2026071419574998800_dgag192-B38","doi-asserted-by":"crossref","first-page":"105540","DOI":"10.1016\/j.jsbmb.2019.105540","article-title":"Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"197","author":"Paizoni","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026071419574998800_dgag192-B39","doi-asserted-by":"crossref","first-page":"848274","DOI":"10.3389\/fendo.2022.848274","article-title":"Components of metabolic syndrome in youth with classical congenital adrenal hyperplasia","volume":"13","author":"Kim","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"04","key":"2026071419574998800_dgag192-B40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0029-1225259","article-title":"Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"27","author":"Kim","year":"2009","journal-title":"Semin Reprod Med"},{"issue":"12","key":"2026071419574998800_dgag192-B41","first-page":"1871","article-title":"Practice variation among pediatric endocrinologists in the dosing of glucocorticoids in young children with congenital adrenal hyperplasia","volume":"10","author":"Al-Rayess","year":"2023","journal-title":"Children (Basel)"},{"issue":"4","key":"2026071419574998800_dgag192-B42","doi-asserted-by":"crossref","first-page":"dgaa071","DOI":"10.1210\/clinem\/dgaa071","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia","volume":"105","author":"Melin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419574998800_dgag192-B43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bcp.14470","article-title":"An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia","volume":"87","author":"Al-Kofahi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2026071419574998800_dgag192-B44","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1210\/clinem\/dgab826","article-title":"Optimizing the timing of highest hydrocortisone dose in children and adolescents with 21-hydroxylase deficiency","volume":"107","author":"Schroder","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071419574998800_dgag192-B45","first-page":"3082","article-title":"Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning","volume":"84","author":"Plat","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574998800_dgag192-B46","doi-asserted-by":"crossref","first-page":"e2647","DOI":"10.1210\/clinem\/dgae836","article-title":"Evaluation of sleep health in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Golob","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419574998800_dgag192-B47","first-page":"e2022304","article-title":"Growth and metabolic syndrome (MetS) criteria in young children with classic congenital adrenal hyperplasia (CAH) treated with corticosteroids (CS)","volume":"93","author":"Abdel Meguid","year":"2022","journal-title":"Acta Biomed"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B48","first-page":"S294","article-title":"Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Egyptian experience","volume":"78","author":"Alashmawy","year":"2012","journal-title":"Horm Res"},{"issue":"4","key":"2026071419574998800_dgag192-B49","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00431-017-2875-2","article-title":"Cardio-metabolic risk factors in youth with classical 21-hydroxylase deficiency","volume":"176","author":"Ariyawatkul","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"4","key":"2026071419574998800_dgag192-B50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1530\/EJE-20-1249","article-title":"International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry","volume":"184","author":"Bacila","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026071419574998800_dgag192-B51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000313368","article-title":"Alterations in lipid and carbohydrate metabolism in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"74","author":"Zimmermann","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"2026071419574998800_dgag192-B52","doi-asserted-by":"crossref","first-page":"E1153","DOI":"10.1210\/jc.2014-4033","article-title":"Increased abdominal adiposity in adolescents and young adults with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"100","author":"Kim","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026071419574998800_dgag192-B53","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1515\/JPEM.2008.21.12.1155","article-title":"Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency","volume":"21","author":"Elnecave","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2026071419574998800_dgag192-B54","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2006-2109","article-title":"Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty","volume":"92","author":"Bonfig","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419574998800_dgag192-B55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/clinem\/dgad514","article-title":"Gonadotropin-releasing hormone agonist therapy and longitudinal bone mineral density in congenital adrenal hyperplasia","volume":"109","author":"Flokas","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419574998800_dgag192-B56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cen.14967","article-title":"Long-term health consequences of congenital adrenal hyperplasia","volume":"101","author":"Pofi","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026071419574998800_dgag192-B57","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/cen.13313","article-title":"Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age","volume":"86","author":"Sarafoglou","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2026071419574998800_dgag192-B58","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1210\/jc.2012-2102","article-title":"Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia","volume":"97","author":"Finkielstain","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026071419574998800_dgag192-B59","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1210\/jc.2009-0942","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation","volume":"94","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419574998800_dgag192-B60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cen.13086","article-title":"Hypertension in children with congenital adrenal hyperplasia","volume":"85","author":"Maccabee-Ryaboy","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026071419574998800_dgag192-B61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/endrev\/bnae026","article-title":"Cardiometabolic aspects of congenital adrenal hyperplasia","volume":"46","author":"Krysiak","year":"2025","journal-title":"Endocr Rev"},{"issue":"3","key":"2026071419574998800_dgag192-B62","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jpeds.2014.11.027","article-title":"The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia","volume":"166","author":"Bomberg","year":"2015","journal-title":"J Pediatr"},{"issue":"2","key":"2026071419574998800_dgag192-B63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1590\/S0004-27302013000200005","article-title":"Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism","volume":"57","author":"Cordeiro","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"2026071419574998800_dgag192-B64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2265.2008.03518.x","article-title":"Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy","volume":"71","author":"Zimmermann","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1-2","key":"2026071419574998800_dgag192-B65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000515833","article-title":"Bone mass in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"94","author":"Espinosa Reyes","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2026071419574998800_dgag192-B66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","article-title":"Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis","volume":"74","author":"Li","year":"2021","journal-title":"Endocrine"},{"key":"2026071419574998800_dgag192-B67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fendo.2020.00493","article-title":"Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"11","author":"Rangaswamaiah","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026071419574998800_dgag192-B68","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1210\/clinem\/dgab712","article-title":"Increased prevalence of fractures in congenital adrenal hyperplasia: a Swedish population-based national cohort study","volume":"107","author":"Falhammar","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574998800_dgag192-B69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2026071419574998800_dgag192-B70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MED.0000000000000545","article-title":"Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?","volume":"27","author":"Gomes","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"2026071419574998800_dgag192-B71","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2014-1805","article-title":"Cardiovascular abnormalities and impaired exercise performance in adolescents with congenital adrenal hyperplasia","volume":"100","author":"Marra","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026071419574998800_dgag192-B72","first-page":"e5247","article-title":"Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia","volume":"106","author":"Torky","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574998800_dgag192-B73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fendo.2019.00212","article-title":"Cardiovascular health in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxilase deficiency","volume":"10","author":"Improda","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2026071419574998800_dgag192-B74","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1515\/jpem-2017-0068","article-title":"Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency","volume":"30","author":"Mooij","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"2026071419574998800_dgag192-B75","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/archdischild-2016-311910","article-title":"Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia","volume":"102","author":"Mooij","year":"2017","journal-title":"Arch Dis Child"},{"issue":"4","key":"2026071419574998800_dgag192-B76","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1210\/clinem\/dgae362","article-title":"Multicenter analysis of cardiometabolic-related diagnoses in youth with congenital adrenal hyperplasia: a PEDSnet study","volume":"110","author":"Chen","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"11-12","key":"2026071419574998800_dgag192-B77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000514130","article-title":"Early adiposity rebound predicts obesity and adiposity in youth with congenital adrenal hyperplasia","volume":"93","author":"Bhullar","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"2026071419574998800_dgag192-B78","doi-asserted-by":"crossref","first-page":"1129584","DOI":"10.3389\/fendo.2023.1129584","article-title":"Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States","volume":"14","author":"Harasymiw","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026071419574998800_dgag192-B79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.psyneuen.2015.06.017","article-title":"Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: a total population study","volume":"60","author":"Engberg","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"2026071419574998800_dgag192-B80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12955-014-0107-2","article-title":"Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil","volume":"12","author":"Gilban","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2026071419574998800_dgag192-B81","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1515\/jpem-2019-0345","article-title":"Assessment of health-related quality of life in Egyptian children and adolescents with congenital adrenal hyperplasia","volume":"33","author":"Musa","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2026071419574998800_dgag192-B82","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12955-017-0769-7","article-title":"Health-related quality of life in children with congenital adrenal hyperplasia","volume":"15","author":"Halper","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2026071419574998800_dgag192-B83","first-page":"156","article-title":"Glucocorticoid dose and type are associated with depression scores in youth with classical congenital adrenal hyperplasia","volume":"18","author":"Liang","year":"2026","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2026071419574998800_dgag192-B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2025.128","article-title":"Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study","author":"Lagerberg","year":"2025","journal-title":"Br J Psychiatry"},{"issue":"1","key":"2026071419574998800_dgag192-B85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3803\/EnM.2021.1328","article-title":"Epidemiology and long-term adverse outcomes in Korean patients with congenital adrenal hyperplasia: a nationwide study","volume":"37","author":"Kim","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2026071419574998800_dgag192-B86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s42000-020-00232-8","article-title":"Behavioral assessment of females with congenital adrenal hyperplasia","volume":"20","author":"Hamed","year":"2021","journal-title":"Hormones"},{"issue":"5","key":"2026071419574998800_dgag192-B87","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1530\/EJE-10-0693","article-title":"Psychiatric characterization of children with genetic causes of hyperandrogenism","volume":"163","author":"Mueller","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2026071419574998800_dgag192-B88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yhbeh.2014.11.014","article-title":"Working memory performance is reduced in children with congenital adrenal hyperplasia","volume":"67","author":"Browne","year":"2015","journal-title":"Horm Behav"},{"key":"2026071419574998800_dgag192-B89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpeds.2021.08.066","article-title":"Behavioral health diagnoses in youth with differences of sex development or congenital adrenal hyperplasia compared with controls: a PEDSnet study","volume":"239","author":"Sewell","year":"2021","journal-title":"J Pediatr"},{"issue":"6","key":"2026071419574998800_dgag192-B90","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/cen.13441","article-title":"Cognitive impairment in adolescents and adults with congenital adrenal hyperplasia","volume":"87","author":"Karlsson","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2026071419574998800_dgag192-B91","doi-asserted-by":"crossref","first-page":"bvaa152","DOI":"10.1210\/jendso\/bvaa152","article-title":"Attention-deficit\/hyperactivity disorder among US children and adolescents with congenital adrenal hyperplasia","volume":"4","author":"Harasymiw","year":"2020","journal-title":"J Endocr Soc"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B92","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1210\/clinem\/dgae759","article-title":"Future directions in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Sarafoglou","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574998800_dgag192-B93","volume-title":"KHINDIVI\u00ae (Hydrocortisone) Oral Solution Full Prescribing Information","author":"Eton Pharmaceuticals","year":"2025"},{"issue":"12","key":"2026071419574998800_dgag192-B94","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1210\/jc.2016-1916","article-title":"A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia","volume":"101","author":"Nella","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419574998800_dgag192-B95","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cen.13813","article-title":"Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia","volume":"89","author":"Mallappa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026071419574998800_dgag192-B96"},{"issue":"5","key":"2026071419574998800_dgag192-B97","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B98","first-page":"bvae163","article-title":"Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study","volume":"8","author":"Auchus","year":"2024","journal-title":"J Endocr Soc"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B99","first-page":"A152","article-title":"Safety and pharmacokinetics of anti-ACTH antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol","volume":"5","author":"Srirangalingam","year":"2024","journal-title":"J Endocr Soc"},{"issue":"Suppl_1","key":"2026071419574998800_dgag192-B100","first-page":"OR25","article-title":"The effects of crinecerfont (NBI-74788), a novel CRF1 receptor antagonist, on adrenal androgens and precursors in patients with classic congenital adrenal hyperplasia: results from a multiple-dose phase 2 study","volume":"4","author":"Auchus","year":"2020","journal-title":"J Endocr Soc"},{"issue":"11","key":"2026071419574998800_dgag192-B101","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419574998800_dgag192-B102","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071419574998800_dgag192-B103","author":"Auchus"},{"issue":"6","key":"2026071419574998800_dgag192-B104","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071419574998800_dgag192-B105","author":"Nokoff"},{"key":"2026071419574998800_dgag192-B106","author":"Geffner"},{"key":"2026071419574998800_dgag192-B107","first-page":"1801","author":"Hamidi","year":"2026"},{"issue":"5","key":"2026071419574998800_dgag192-B108","first-page":"G25","article-title":"European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"190","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419574998800_dgag192-B109","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-3476(05)80128-3","article-title":"Cortisol production rate in childhood and adolescence","volume":"117","author":"Linder","year":"1990","journal-title":"J Pediatr"},{"issue":"1","key":"2026071419574998800_dgag192-B110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2003-030440","article-title":"Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women","volume":"89","author":"Purnell","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026071419574998800_dgag192-B111","doi-asserted-by":"crossref","first-page":"e2171","DOI":"10.1210\/clinem\/dgae824","article-title":"Adult height following prepubertal treatment with antiandrogen, aromatase inhibitor, and reduced hydrocortisone in CAH","volume":"110","author":"Merke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574998800_dgag192-B112","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1373\/clinchem.2010.146035","article-title":"Monitoring of therapy in congenital adrenal hyperplasia","volume":"56","author":"Dauber","year":"2010","journal-title":"Clin Chem"},{"issue":"1","key":"2026071419574998800_dgag192-B113","doi-asserted-by":"crossref","first-page":"e000198","DOI":"10.1136\/bmjpo-2017-000198","article-title":"Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing","volume":"2","author":"Madathilethu","year":"2018","journal-title":"BMJ Paediatr Open"},{"issue":"1-2","key":"2026071419574998800_dgag192-B114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2018.04.054","article-title":"How close is the dose? Manipulation of 10\u202fmg hydrocortisone tablets to provide appropriate doses to children","volume":"545","author":"Watson","year":"2018","journal-title":"Int J Pharm"},{"issue":"4","key":"2026071419574998800_dgag192-B115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.106.4.767","article-title":"Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth","volume":"106","author":"Rivkees","year":"2000","journal-title":"Pediatrics"},{"key":"2026071419574998800_dgag192-B116","volume-title":"The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence","author":"Wilkins","year":"1950","edition":"1st ed"},{"issue":"2","key":"2026071419574998800_dgag192-B117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.beem.2008.10.010","article-title":"Management of the child with congenital adrenal hyperplasia","volume":"23","author":"Hindmarsh","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026071419574998800_dgag192-B118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jcem-33-1-14","article-title":"Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects","volume":"33","author":"Weitzman","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2026071419574998800_dgag192-B119","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/S0024-3205(97)01008-4","article-title":"Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity","volume":"61","author":"Pruessner","year":"1997","journal-title":"Life Sci"},{"issue":"1","key":"2026071419574998800_dgag192-B120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/JIM.0000000000000121","article-title":"Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia","volume":"63","author":"Sarafoglou","year":"2015","journal-title":"J Investig Med"},{"issue":"3","key":"2026071419574998800_dgag192-B121","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.2012.04502.x","article-title":"Deconvolution analysis of 24-h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy","volume":"78","author":"Peters","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026071419574998800_dgag192-B122","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1210\/jcem.86.6.7522","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6):","key":"2026071419574998800_dgag192-B123","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000374112","article-title":"Influence of 17-hydroxyprogesterone, progesterone and sex steroids on mineralocorticoid receptor transactivation in congenital adrenal hyperplasia","volume":"83","author":"Mooij","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2026071419574998800_dgag192-B124","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ajh\/hpv087","article-title":"Blood pressure in a large cohort of children and adolescents with classic adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency","volume":"29","author":"Bonfig","year":"2016","journal-title":"Am J Hypertens"},{"issue":"6","key":"2026071419574998800_dgag192-B125","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/cen.12498","article-title":"Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age","volume":"81","author":"Bonfig","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026071419574998800_dgag192-B126","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/archdischild-2016-311223","article-title":"Symptomatic adrenal suppression among children in Canada","volume":"102","author":"Goldbloom","year":"2017","journal-title":"Arch Dis Child"},{"issue":"1","key":"2026071419574998800_dgag192-B127","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2826.2010.02074.x","article-title":"The vasopressin V1b receptor modulates plasma corticosterone responses to dehydration-induced stress","volume":"23","author":"Roberts","year":"2011","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2026071419574998800_dgag192-B128","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1210\/clinem\/dgaa694","article-title":"Real-world estimates of adrenal insufficiency-related adverse events in children with congenital adrenal hyperplasia","volume":"106","author":"Ali","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag192\/68209616\/dgag192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/e1937\/68209616\/dgag192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/e1937\/68209616\/dgag192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:58:23Z","timestamp":1784073503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/8\/e1937\/8667182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":128,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag192","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,4]]}}}